WANBURY Stock Overview
Manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Wanbury Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹303.94 |
| 52 Week High | ₹323.53 |
| 52 Week Low | ₹123.00 |
| Beta | 0.65 |
| 1 Month Change | 38.04% |
| 3 Month Change | 14.47% |
| 1 Year Change | 130.78% |
| 3 Year Change | 275.93% |
| 5 Year Change | 1,560.87% |
| Change since IPO | 121.05% |
Recent News & Updates
Wanbury Limited's (NSE:WANBURY) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Dec 12
We Believe Wanbury's (NSE:WANBURY) Earnings Are A Poor Guide For Its Profitability
Nov 23Recent updates
Wanbury Limited's (NSE:WANBURY) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Dec 12We Believe Wanbury's (NSE:WANBURY) Earnings Are A Poor Guide For Its Profitability
Nov 23Is Wanbury (NSE:WANBURY) Using Too Much Debt?
Nov 18Wanbury Limited (NSE:WANBURY) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Sep 13Wanbury Limited (NSE:WANBURY) Might Not Be As Mispriced As It Looks
Jul 16Statutory Earnings May Not Be The Best Way To Understand Wanbury's (NSE:WANBURY) True Position
May 24These 4 Measures Indicate That Wanbury (NSE:WANBURY) Is Using Debt Reasonably Well
May 21The Market Doesn't Like What It Sees From Wanbury Limited's (NSE:WANBURY) Earnings Yet
Mar 19Wanbury Limited's (NSE:WANBURY) Shares Leap 42% Yet They're Still Not Telling The Full Story
Dec 18Estimating The Fair Value Of Wanbury Limited (NSE:WANBURY)
Sep 07Not Many Are Piling Into Wanbury Limited (NSE:WANBURY) Just Yet
Jul 16Calculating The Intrinsic Value Of Wanbury Limited (NSE:WANBURY)
Oct 27A Look At The Fair Value Of Wanbury Limited (NSE:WANBURY)
Apr 14A Look At The Fair Value Of Wanbury Limited (NSE:WANBURY)
Dec 29Are Wanbury's (NSE:WANBURY) Statutory Earnings A Good Guide To Its Underlying Profitability?
Sep 09Shareholder Returns
| WANBURY | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.6% | -1.0% | -0.9% |
| 1Y | 130.8% | 39.2% | 22.5% |
Return vs Industry: WANBURY exceeded the Indian Pharmaceuticals industry which returned 39.2% over the past year.
Return vs Market: WANBURY exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility
| WANBURY volatility | |
|---|---|
| WANBURY Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: WANBURY's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: WANBURY's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,491 | Mohan Rayana | www.wanbury.com |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.
Wanbury Limited Fundamentals Summary
| WANBURY fundamental statistics | |
|---|---|
| Market cap | ₹10.00b |
| Earnings (TTM) | ₹529.62m |
| Revenue (TTM) | ₹5.77b |
18.9x
P/E Ratio1.7x
P/S RatioIs WANBURY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WANBURY income statement (TTM) | |
|---|---|
| Revenue | ₹5.77b |
| Cost of Revenue | ₹2.94b |
| Gross Profit | ₹2.83b |
| Other Expenses | ₹2.30b |
| Earnings | ₹529.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.17 |
| Gross Margin | 49.08% |
| Net Profit Margin | 9.18% |
| Debt/Equity Ratio | 453.1% |
How did WANBURY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 22:44 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wanbury Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|